Re: Coronavirus and psoriasis reporting registry

Dear Colleagues,

Given the interest in the emerging and evolving coronavirus (COVID-19) epidemic and the questions regarding how this will impact patients with psoriasis, many of whom may be undergoing treatment with immune suppression, we decided to create a secure, online, de-identified Personal Health Identifier (PHI)-free reporting registry. We encourage clinicians who treat psoriasis patients worldwide to report ALL cases of COVID-19 in their psoriasis patients, regardless of severity (including asymptomatic patients detected through public health screening). Reporting a case to this Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE)-Psoriasis registry should take approximately 5 minutes or less. No patient identifying information is required. With the collaboration of our entire psoriasis community, we will rapidly be able to define the impact of COVID-19 on patients with psoriasis and how factors such as age, comorbidities, and psoriasis treatments impact COVID outcomes.

Key points:

1. This is an international effort—we are counting on robust participation and collaboration.
2. On the project website, covidpso.org, we will provide regularly updated summary information about reported cases, including numbers of cases by country, number of cases by treatment, etc., so the entire psoriasis community has access to these data.
3. The registry contains only de-identified data, in accordance with HIPAA Safe Harbor De-Identification standards.
4. The Wake Forest School of Medicine Institutional Review Board has determined that storage and analysis of de-identified data does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102].

We hope you will actively contribute to this voluntary reporting system. Through broadscale participation and collaboration, we will be able to answer these very pressing questions for our psoriasis patients and their caregivers.

To report a case of coronavirus, click here or visit www.covidpso.org.

If you have any questions, please reach out to COVID_PSO@wakehealth.edu

In addition to the reporting cases of COVID-19 to SECURE-Psoriasis, we also encourage reporting to your local public health agency where applicable.

Sincerely,

Steven R. Feldman, MD, PhD (Professor of Dermatology, Wake Forest School of Medicine)

William W. Huang, MD, MPH (Associate Professor of Dermatology, Wake Forest School of Medicine)
What is SECURE-PSORIASIS?

Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-PSORIASIS) is an international, pediatric and adult database to monitor and report on outcomes of COVID-19 occurring in psoriasis patients.

We are committed to collaboration, transparency, and rapid data sharing with the international pediatric and adult psoriasis community. By working across borders, we will rapidly be able to define the impact of COVID-19 on patients with psoriasis and explore how factors such as age, comorbidities, and psoriasis treatments impact COVID outcomes.

How can a provider report a case?

All clinicians who treat psoriasis worldwide are highly encouraged to report ALL cases of COVID-19 in their psoriasis patients, regardless of severity. Reporting should take at most 5 minutes.

Please report only confirmed COVID-19 cases, and report after a minimum of 7 days from COVID diagnosis and sufficient time has passed to observe the disease course through resolution of acute illness or death.

We find ourselves in an unprecedented situation and, truly, we are all in this together.

Who is organizing this project?

This project is being led by Drs. Steven R. Feldman (Professor of Dermatology) and William W. Huang (Associate Professor of Dermatology) at the Wake Forest School of Medicine in Winston-Salem, North Carolina. SECURE-PSORIASIS is produced in collaboration with SECURE-IBD, a database to monitor and report on outcomes of COVID-19 in IBD patients. SECURE-IBD is led by Drs. Michael Kappelman (Pediatric Gastroenterologist) and Erica Brenner (Pediatric Gastroenterology fellow) at the University of North Carolina at Chapel Hill, and Dr. Ryan Ungaro (Gastroenterologist) at the Icahn School of Medicine at Mount Sinai, New York.

The database contains only de-identified data, in accordance with HIPAA Safe Harbor De-Identification standards. The Wake Forest School of Medicine Institutional Review Board has determined that storage and analysis of de-identified data does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102].

Please visit us at covidpso.org for updated information or to report a case.